Immunome (IMNM) Current Deferred Revenue (2023 - 2025)
Immunome's (IMNM) quarterly Current Deferred Revenue came in at $4.0 million in Q1 2025, down 68.5% YoY from $12.7 million in Q1 2024, and down 42.16% on a QoQ basis from $6.9 million in Q4 2024.
Immunome (IMNM) Current Deferred Revenue (2023 - 2025) Analysis & Trends
Immunome (IMNM) has 3 years of Current Deferred Revenue data on file, last reported at $4.0 million in Q1 2025.
- Quarterly Current Deferred Revenue fell 68.5% year-over-year to $4.0 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $4.0 million (down 68.5% YoY) and the FY2024 annual result came in at $6.9 million, down 56.57% from the prior year.
- Current Deferred Revenue slipped to $4.0 million in Q1 2025, from $6.9 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $27.6 million in Q1 2023 to a low of $4.0 million in Q1 2025.
- A 3-year average of $14.4 million and a median of $12.7 million in 2024 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue slumped 42.92% — and 2025, when it slumped 68.5%.
- Tracing IMNM's Current Deferred Revenue over 3 years: stood at $16.0 million in 2023, then plunged by 56.57% to $6.9 million in 2024, then tumbled by 42.16% to $4.0 million in 2025.
- The last three Current Deferred Revenue figures came in at $4.0 million (Q1 2025), $6.9 million (Q4 2024), and $9.7 million (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 4.02 Mn |
| Dec 31, 2024 | 6.94 Mn |
| Sep 30, 2024 | 9.68 Mn |
| Jun 30, 2024 | 12.59 Mn |
| Mar 31, 2024 | 12.75 Mn |
| Dec 31, 2023 | 15.98 Mn |
| Sep 30, 2023 | 16.96 Mn |
| Jun 30, 2023 | 23.37 Mn |
| Mar 31, 2023 | 27.64 Mn |